|
1
|
Peyssonnaux C and Eychène A: The
Raf/MEK/ERK pathway: New concepts of activation. Biol Cell.
93:53–62. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huebner C, Weber R and Lloydd R: A HRM
assay for identification of low level BRAF V600E and V600K
mutations using the CADMA principle in FFPE specimens. Pathology.
49:776–783. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen D, Zhang LQ, Huang JF, Liu K, Chuai
ZR, Yang Z, Wang YX, Shi DC, Liu Q, Huang Q, et al: BRAF mutations
in patients with non-small cell lung cancer: A systematic review
and meta-analysis. PLoS One. 9:e1013542014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tamiya M, Tamiya A, Shiroyama T, Takeoka
S, Naito Y, Omachi N, Kimura Y, Morishita N, Suzuki H, Okamoto N,
et al: Phase1 study of cisplatin plus pemetrexed with erlotinib and
bevacizumab for chemotherapy-naïve advanced non-squamous non-small
cell lung cancer with EGFR mutations. Invest New Drugs. Nov
4–2017.(Epub ahead of print). PubMed/NCBI
|
|
5
|
Oxnard GR, Paweletz CP and Sholl LM:
Genomic analysis of plasma cell-free DNA in patients With Cancer.
JAMA Oncol. 3:740–741. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grzywa TM, Paskal W and Włodarski PK:
Intratumor and intertumor heterogeneity in melanoma. Transl Oncol.
10:956–975. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Martelotto LG, Ng CK, Piscuoglio S,
Weigelt B and Reis-Filho JS: Breast cancer intra-tumor
heterogeneity. Breast Cancer Res. 16:2102014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Villaruz LC, Socinski MA, Abberbock S,
Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M,
Franklin WA, Camidge DR, et al: Clinicopathologic features and
outcomes of patients with lung adenocarcinomas harboring BRAF
mutations in the Lung Cancer Mutation Consortium. Cancer.
121:448–456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Czirbesz K, Gorka E, Balatoni T, Pánczél
G, Melegh K, Kovács P, Gézsi A and Liszkay G: Efficacy of
vemurafenib treatment in 43 metastatic melanoma patients with BRAF
mutation. Single-institute retrospective analysis, early real-life
survival data. Pathol Oncol Res. Sep 29–2017.(Epub ahead of print).
View Article : Google Scholar
|
|
10
|
Noeparast A, Teugels E, Giron P,
Verschelden G, De Brakeleer S, Decoster L and De Grève J: Non-V600
BRAF mutations recurrently found in lung cancer predict sensitivity
to the combination of Trametinib and Dabrafenib. Oncotarget.
8:60094–60108. 2016.PubMed/NCBI
|
|
11
|
Planchard D, Besse B, Groen HJM, Souquet
PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, et
al: Dabrafenib plus trametinib in patients with previously treated
BRAF(V600E)-mutant metastatic non-small cell lung cancer: An
open-label, multicentre phase 2 trial. Lancet Oncol. 17:984–993.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hyman DM, Puzanov I, Subbiah V, Faris JE,
Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, et al:
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600
Mutations. N Engl J Med. 373:726–736. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tsoulos N, Papadopoulou E, Metaxa-Mariatou
V, Tsaousis G, Efstathiadou C, Tounta G, Scapeti A, Bourkoula E,
Zarogoulidis P, Pentheroudakis G, et al: Tumor molecular profiling
of NSCLC patients using next generation sequencing. Oncol Rep.
38:3419–3429. 2017.PubMed/NCBI
|
|
14
|
Drilon A, Wang L, Arcila ME,
Balasubramanian S, Greenbowe JR, Ross JS, Stephens P, Lipson D,
Miller VA, Kris MG, et al: Broad, Hybrid Capture-Based
Next-Generation Sequencing Identifies Actionable Genomic
Alterations in Lung Adenocarcinomas Otherwise Negative for Such
Alterations by Other Genomic Testing Approaches. Clin Cancer Res.
21:3631–3639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chaft JE, Arcila ME, Paik PK, Lau C, Riely
GJ, Pietanza MC, Zakowski MF, Rusch V, Sima CS, Ladanyi M, et al:
Coexistence of PIK3CA and other oncogene mutations in lung
adenocarcinoma-rationale for comprehensive mutation profiling. Mol
Cancer Ther. 11:485–491. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Suh JH, Johnson A, Albacker L, Wang K,
Chmielecki J, Frampton G, Gay L, Elvin JA, Vergilio JA, Ali S, et
al: Comprehensive Genomic Profiling Facilitates Implementation of
the National Comprehensive Cancer Network Guidelines for Lung
Cancer Biomarker Testing and Identifies Patients Who May Benefit
From Enrollment in Mechanism-Driven Clinical Trials: Comprehensive
genomic profiling facilitates implementation of the national
comprehensive cancer network guidelines for lung cancer biomarker
testing and identifies patients who may benefit from enrollment in
mechanism-driven clinical trials. Oncologist. 21:684–691. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xiong L, Cui S, Ding J, Sun Y, Zhang L,
Zhao Y, Gu A, Chu T, Wang H, Zhong H, et al: Dynamics of EGFR
mutations in plasma recapitulates the clinical response to
EGFR-TKIs in NSCLC patients. Oncotarget. 8:63846–63856. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shan L, Wang Z, Guo L, Sun H, Qiu T, Ling
Y, Li W, Li L, Liu X, Zheng B, et al: Concurrence of EGFR
amplification and sensitizing mutations indicate a better survival
benefit from EGFR-TKI therapy in lung adenocarcinoma patients. Lung
Cancer. 89:337–342. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li H, Wang Y, Su F, Li J and Gong P:
Monitoring of cyclooxygenase-2 levels can predict EGFR mutations
and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
Int J Clin Exp Pathol. 8:5577–5583. 2015.PubMed/NCBI
|
